An update on male hypogonadism therapy
Open accessThe DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Men who have symptoms associated with persistently low serum total testosterone level should be assessed for testosterone replacement therapy. AREAS COVERED: Acute and chronic illnesses are associated with low serum testosterone and these should be recognized and treated. Once the diagnosis of male hypogonadism is made, the benefits of testosterone treatment usually outweigh the risks. Without contraindications, the patient should be offered testosterone replacement therapy. The options of testosterone delivery systems (injections, transdermal patches/gels, buccal tablets, capsules and implants) have increased in the last decade. Testosterone improves symptoms and signs of hypogonadism such as sexual function and energy, increases bone density and lean mass and decreases visceral adiposity. In men who desire fertility and who have secondary hypogonadism, testosterone can be withdrawn and the patients can be placed on gonadotropins. New modified designer androgens and selective androgen receptor modulators have been in preclinical and clinical trials for some time. None of these have been assessed for the treatment of male hypogonadism. EXPERT OPINION: Despite the lack of prospective long-term data from randomized, controlled clinical trials of testosterone treatment on prostate health and cardiovascular disease risk, the available evidence suggests that testosterone therapy should be offered to symptomatic hypogonadal men.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men
Harman, S. M., Metter, E. J., Tobin, J. D., Pearson, J., & Blackman, M. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7219 · Cited by 2,760 · cited 2×
“Hypogonadism diagnosed based on serum total testosterone levels was estimated to be < 5% in men aged between 20 -- 30 years, 12% in men 50 -- 60 years, and between 19 and 49% in men aged 60 -- 80 years in the Baltimore Longitudinal Study of Aging [4].”
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954 · cited 10×
“, 400 -- 700 ng/dl) and resolution or reduction in symptoms of hypogonadism [1].”
InfluentialSelf-citationThe effects of supraphysiologic doses of testosterone on muscle size and strength in normal men
Bhasin, S., Storer, T. W., Berman, N., Callegari, C., Clevenger, B., Phillips, J., Bunnell, T. J., Tricker, R., Shirazi, A., & Casaburi, R. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607043350101 · Cited by 1,659
Identification of late-onset hypogonadism in middle-aged and elderly men
Wu, F. C. W., Tajar, A., Beynon, J. M., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F. F., Forti, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911101 · Cited by 1,544 · cited 4×
“If the serum testosterone is over 370 ng/dl (12 nmol/l), it is unlikely the subject is hypogonadal [6] unless the patient has a very high sex hormone binding globulin (SHBG) resulting in low free or bioavailable testosterone.”
InfluentialAdverse Events Associated with Testosterone Administration
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000485 · Cited by 1,494
Rosner, W., Auchus, R. J., Azziz, R., Sluss, P. M., & Raff, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1864 · Cited by 1,176 · cited 3×
“In recent years it is recognized that serum testosterone levels measured in different laboratories even using similar methodology have large interlaboratory variations [17-20].”
Vigen, R. (2013) · JAMA · doi:10.1001/jama.2013.280386 · Cited by 1,003 · cited 2×
“However, in another study in US veterans with low testosterone levels who had undergone coronary angiography, testosterone replacement therapy was associated with an increase in risks of myocardial infarction, ischemic stroke and all-cause mortality [15].”
Testosterone dose-response relationships in healthy young men
Bhasin, S., Woodhouse, L., Casaburi, R., Singh, A. B., Bhasin, D., Berman, N., Chen, X., Yarasheski, K. E., Magliano, L., Dzekov, C., et al. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.6.e1172 · Cited by 967 · cited 1×
“Studies have shown that testosterone may have a threshold effect on some parameters such as sexual function but there appears to be a dose-related response to testosterone treatment for muscle mass, fat mass and hemoglobin and hematocrit [26,27].”
Wu, F. C. W., Tajar, A., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F., Forti, G., Giwercman, A., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1972 · Cited by 939 · cited 2×
“Many of these factors can be modified by lifestyle changes or disease-specific interventions to prevent age-related decline in testosterone [11].”
Low Serum Testosterone and Mortality in Older Men
Laughlin, G. A., Barrett-Connor, E., & Bergstrom, J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1792 · Cited by 798
Kapoor, D., Goodwin, E., Channer, K. S., & Jones, T. H. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02166 · Cited by 791 · cited 2×
“The decrease in central adiposity and minor improvements in insulin sensitivity and hemoglobin A1C have also been reported in individuals with hypogonadism and metabolic syndrome and/or type 2 diabetes [2,57,58,61-66].”
Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men
Finkelstein, J. S., Lee, H., Burnett-Bowie, S.-A. M., Pallais, J. C., Yu, E. W., Borges, L. F., Jones, B. F., Barry, C. V., Wulczyn, K. E., Thomas, B. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1206168 · Cited by 782
Khaw, K.-T., Dowsett, M., Folkerd, E., Bingham, S., Wareham, N., Luben, R., Welch, A., & Day, N. (2007) · Circulation · doi:10.1161/circulationaha.107.719005 · Cited by 743 · cited 1×
“3 Testosterone therapy and cardiovascular disease risk in men Several epidemiological studies showed that men with low testosterone have higher all-cause mortality, which is mainly due to increase in cardiovascular disease [87-91].”
Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men
Finkle, W. D., Greenland, S., Ridgeway, G. K., Adams, J. L., Frasco, M. A., Cook, M. B., Fraumeni, J. F., & Hoover, R. N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085805 · Cited by 735
Calof, O. M., Singh, A. B., Lee, M. L., Kenny, A. M., Urban, R. J., Tenover, J. L., & Bhasin, S. (2005) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/60.11.1451 · Cited by 728 · cited 6×
“Further large scale longitudinal studies are needed to ascertain the effects of testosterone replacement therapy in men with OSA.”
InfluentialPrevalence of Symptomatic Androgen Deficiency in Men
Araujo, A. B., Esche, G. R., Kupelian, V., O’Donnell, A. B., Travison, T. G., Williams, R. E., Clark, R. V., & McKinlay, J. B. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1245 · Cited by 720 · cited 1×
“Male hypogonadism increases with age and with multiple co-morbid conditions in several epidemiologic studies [5-7].”
Adverse Effects of Testosterone Therapy in Adult Men: A Systematic Review and Meta-Analysis
Fernández-Balsells, M. M., Murad, M. H., Lane, M., Lampropulos, J. F., Albuquerque, F., Mullan, R. J., Agrwal, N., Elamin, M. B., Gallegos-Orozco, J. F., Wang, A. T., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2575 · Cited by 713
Isidori, A. M., Giannetta, E., Greco, E. A., Gianfrilli, D., Bonifacio, V., Isidori, A., Lenzi, A., & Fabbri, A. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02339.x · Cited by 695
Wang, C., Cunningham, G., Dobs, A., Iranmanesh, A., Matsumoto, A. M., Snyder, P. J., Weber, T., Berman, N., Hull, L., & Swerdloff, R. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032006 · Cited by 656 · cited 3×
“Testosterone replacement therapy improves sexual function (libido and erectile function) when testosterone levels are restored to the normal range in younger hypogonadal men [31-33].”
Self-citationSrinivas-Shankar, U., Roberts, S. A., Connolly, M. J., O'Connell, M. D. L., Adams, J. E., Oldham, J. A., & Wu, F. C. W. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1251 · Cited by 629 · cited 2×
“In randomized trials in middle-aged and older men, testosterone administration is associated with increase in LBM, reduction in fat mass and increase in muscle strength when compared with placebo [41,48-50].”
Araujo, A. B., O’Donnell, A. B., Brambilla, D. J., Simpson, W. B., Longcope, C., Matsumoto, A. M., & McKinlay, J. B. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031719 · Cited by 591 · cited 1×
“Male hypogonadism increases with age and with multiple co-morbid conditions in several epidemiologic studies [5-7].”
English, K. M., Steeds, R. P., Jones, T. H., Diver, M. J., & Channer, K. S. (2000) · Circulation · doi:10.1161/01.cir.102.16.1906 · Cited by 582
Wang, C., Catlin, D. H., Demers, L. M., Starcevic, B., & Swerdloff, R. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031287 · Cited by 580 · cited 2×
“In recent years it is recognized that serum testosterone levels measured in different laboratories even using similar methodology have large interlaboratory variations [17-20].”
Self-citationPage, S. T., Amory, J. K., Bowman, F. D., Anawalt, B. D., Matsumoto, A. M., Bremner, W. J., & Tenover, J. L. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1933 · Cited by 566 · cited 2×
“While the significant weight loss requires careful confirmation, randomized controlled trials showed that testosterone replacement therapy reduced body fat mass, regional fat distribution and waist circumference in hypogonadal men with and without obesity [48,53-61].”
Long-term effect of testosterone therapy on bone mineral density in hypogonadal men
Behre, H. M., Kliesch, S., Leifke, E., Link, T. M., & Nieschlag, E. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.8.4163 · Cited by 559 · cited 1×
“Testosterone replacement therapy increases bone mineral density in hypogonadal younger and older men [32,39-46].”
Jones, T. H., Arver, S., Behre, H. M., Buvat, J., Meuleman, E., Moncada, I., Morales, A. M., Volterrani, M., Yellowlees, A., Howell, J. D., et al. (2011) · Diabetes Care · doi:10.2337/dc10-1233 · Cited by 548 · cited 3×
“The decrease in central adiposity and minor improvements in insulin sensitivity and hemoglobin A1C have also been reported in individuals with hypogonadism and metabolic syndrome and/or type 2 diabetes [2,57,58,61-66].”
Emmelot-Vonk, M. H., Verhaar, H. J. J., Nakhai Pour, H. R., Aleman, A., Lock, T. M. T. W., Bosch, J. L. H. R., Grobbee, D. E., & van der Schouw, Y. T. (2008) · JAMA · doi:10.1001/jama.2007.51 · Cited by 518
Effects of testosterone on sexual function in men: results of a meta‐analysis
Isidori, A. M., Giannetta, E., Gianfrilli, D., Greco, E. A., Bonifacio, V., Aversa, A., Isidori, A., Fabbri, A., & Lenzi, A. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02350.x · Cited by 492 · cited 2×
“Testosterone replacement therapy improves sexual function (libido and erectile function) when testosterone levels are restored to the normal range in younger hypogonadal men [31-33].”
Amory, J. K., Watts, N. B., Easley, K. A., Sutton, P. R., Anawalt, B. D., Matsumoto, A. M., Bremner, W. J., & Tenover, J. L. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031110 · Cited by 475 · cited 2×
“The concomitant use of testosterone and 5 a reductase inhibitors in hypogonadal men older men with or without benign prostate hyperplasia resulted in lower PSA and smaller prostate volume compared to those who did not received 5 a reductase inhibitor [46,105].”
Corona, G., Rastrelli, G., Monami, M., Saad, F., Luconi, M., Lucchese, M., Facchiano, E., Sforza, A., Forti, G., Mannucci, E., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-12-0955 · Cited by 414
Travison, T. G., Araujo, A. B., Kupelian, V., O’Donnell, A. B., & McKinlay, J. B. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1859 · Cited by 410
Effects of graded doses of testosterone on erythropoiesis in healthy young and older men
Coviello, A. D., Kaplan, B., Lakshman, K. M., Chen, T., Singh, A. B., & Bhasin, S. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1692 · Cited by 404
Marks, L. S., Mazer, N. A., Mostaghel, E., Hess, D. L., Dorey, F. J., Epstein, J. I., Veltri, R. W., Makarov, D. V., Partin, A. W., Bostwick, D. G., et al. (2006) · JAMA · doi:10.1001/jama.296.19.2351 · Cited by 400 · cited 1×
“Hypogonadal men treated with testosterone do not have a linear dose response of prostatic specific antigen (PSA) levels, and unless the pre-treatment testosterone levels are extremely low, do not increase intraprostatic testosterone and DHT levels [55,97].”
Dobs, A. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.10.3469 · Cited by 381 · cited 3×
“There is a greater risk of erythrocytosis with higher maximal peak in testosterone levels with IM injections when compared with transdermal formulations [79].”
Type 2 diabetes mellitus and testosterone: a meta-analysis study: Type 2 diabetes and testosterone
Corona, G., Monami, M., Rastrelli, G., Aversa, A., Sforza, A., Lenzi, A., Forti, G., Mannucci, E., & Maggi, M. (2011) · International Journal of Andrology · doi:10.1111/j.1365-2605.2010.01117.x · Cited by 370
Wang, C., Jackson, G., Jones, T. H., Matsumoto, A. M., Nehra, A., Perelman, M. A., Swerdloff, R. S., Traish, A., Zitzmann, M., & Cunningham, G. (2011) · Diabetes Care · doi:10.2337/dc10-2339 · Cited by 366 · cited 4×
“The decrease in central adiposity and minor improvements in insulin sensitivity and hemoglobin A1C have also been reported in individuals with hypogonadism and metabolic syndrome and/or type 2 diabetes [2,57,58,61-66].”
InfluentialSelf-citationEnglish, K. (2000) · European Heart Journal · doi:10.1053/euhj.1999.1873 · Cited by 350
Heufelder, A. E., Saad, F., Bunck, M. C., & Gooren, L. (2009) · Journal of Andrology · doi:10.2164/jandrol.108.007005 · Cited by 349 · cited 2×
“The decrease in central adiposity and minor improvements in insulin sensitivity and hemoglobin A1C have also been reported in individuals with hypogonadism and metabolic syndrome and/or type 2 diabetes [2,57,58,61-66].”
Androgen Treatment of Abdominally Obese Men
Mårin, P., Holmtäng, S., Gustafsson, C., Jönsson, ‡., Kvist, ‡., Elander, A., Eldh, J., Sjöström, L., Holm, G., & Björntorp, P. (1993) · Obesity Research · doi:10.1002/j.1550-8528.1993.tb00618.x · Cited by 345 · cited 1×
“While the significant weight loss requires careful confirmation, randomized controlled trials showed that testosterone replacement therapy reduced body fat mass, regional fat distribution and waist circumference in hypogonadal men with and without obesity [48,53-61].”
Pope, H. G., Cohane, G. H., Kanayama, G., Siegel, A. J., & Hudson, J. I. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.105 · Cited by 341
Trends in androgen prescribing in the United States, 2001 to 2011
Baillargeon, J., Urban, R. J., Ottenbacher, K. J., Pierson, K. S., & Goodwin, J. S. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.6895 · Cited by 336 · cited 1×
“These factors contribute to a marked increase in the number of testosterone prescription in the US, Europe and Australia in the past 10 -- 15 years [12-14].”
Brand, J. S., van der Tweel, I., Grobbee, D. E., Emmelot-Vonk, M. H., & van der Schouw, Y. T. (2011) · International Journal of Epidemiology · doi:10.1093/ije/dyq158 · Cited by 334 · cited 1×
“However recent studies showed that in obese men, total and free testosterone as well as SHBG levels are all low [54,153].”
Tracz, M. J., Sideras, K., Boloña, E. R., Haddad, R. M., Kennedy, C. C., Uraga, M. V., Caples, S. M., Erwin, P. J., & Montori, V. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0036 · Cited by 275 · cited 1×
“Meta-analysis studies have also shown testosterone replacement therapy increases bone mineral density and reduces rate of bone loss [39,47].”
The Short-Term Effects of High-Dose Testosterone on Sleep, Breathing, and Function in Older Men
Liu, P. Y., Yee, B., Wishart, S. M., Jimenez, M., Jung, D. G., Grunstein, R. R., & Handelsman, D. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030236 · Cited by 275
Sikaris, K., McLachlan, R. I., Kazlauskas, R., de Kretser, D., Holden, C. A., & Handelsman, D. J. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0962 · Cited by 259
Toward Excellence in Testosterone Testing: A Consensus Statement
Rosner, W., & Vesper, H. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1314 · Cited by 248 · cited 1×
“The Center of Disease Control is establishing a standardization program where testosterone assays are accuracy based and not only precision based (precision-based proficiency testing is commonly used for laboratory certification) [21].”
Low serum testosterone and increased mortality in men with coronary heart disease
Malkin, C. J., Pugh, P. J., Morris, P. D., Asif, S., Jones, T. H., & Channer, K. S. (2010) · Heart · doi:10.1136/hrt.2010.195412 · Cited by 236 · cited 1×
“3 Testosterone therapy and cardiovascular disease risk in men Several epidemiological studies showed that men with low testosterone have higher all-cause mortality, which is mainly due to increase in cardiovascular disease [87-91].”
Testosterone treatment for men with chronic heart failure
Pugh, P. J., Jones, R. D., West, J. N., Jones, T. H., & Channer, K. S. (2004) · Heart · doi:10.1136/hrt.2003.014639 · Cited by 221 · cited 1×
“Small studies have demonstrated that testosterone causes coronary vasodilation, improves performance in cardiac stress tests and heart failure [71-74].”
Yialamas, M. A., Dwyer, A. A., Hanley, E., Lee, H., Pitteloud, N., & Hayes, F. J. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0454 · Cited by 220 · cited 1×
“The decrease in central adiposity and minor improvements in insulin sensitivity and hemoglobin A1C have also been reported in individuals with hypogonadism and metabolic syndrome and/or type 2 diabetes [2,57,58,61-66].”
Zitzmann, M., & Nieschlag, E. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0620 · Cited by 216 · cited 1×
“The stimulation of hematopoiesis is influenced by age and appears to be more pronounced in older men [82,83].”
BURRIS, A. S., RODBARD, H. W., WINTERS, S. J., & SHERINS, R. J. (1988) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-66-6-1144 · Cited by 185 · cited 2×
“Many patients with congenital hypogonadotropic hypogonadism require hCG and FSH to complete spermatogenesis while acquired hypogonadotropic hypogonadism may be managed with hCG alone [143,144].”
Boloña, E. R., Uraga, M. V., Haddad, R. M., Tracz, M. J., Sideras, K., Kennedy, C. C., Caples, S. M., Erwin, P. J., & Montori, V. M. (2007) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60963-4 · Cited by 184 · cited 1×
“There is conflicting information regarding the ability of testosterone to improve erectile dysfunction independent of the effects on libido [31,34-38].”
Testosterone Replacement Therapy in Patients with Prostate Cancer After Radical Prostatectomy
Pastuszak, A. W., Pearlman, A. M., Lai, W. S., Godoy, G., Sathyamoorthy, K., Liu, J. S., Miles, B. J., Lipshultz, L. I., & Khera, M. (2013) · Journal of Urology · doi:10.1016/j.juro.2013.02.002 · Cited by 183 · cited 1×
“However, small scale clinical studies showed that in men with low grade or localized prostate cancer who had prostatectomy, serum PSA levels that are undetectable, and who had symptomatic hypogonadism, replacement with testosterone did not result in increase in PSA levels or increase in the recurrence of prostate canc…”
Predictive accuracy and sources of variability in calculated free testosterone estimates
Sartorius, G., Ly, L. P., Sikaris, K., McLachlan, R., & Handelsman, D. J. (2009) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1258/acb.2008.008171 · Cited by 175 · cited 1×
“Calculated free testosterone using various formulae will give free testosterone levels depending on the formulae used and accuracy and precision of the assays for total testosterone and SHBG levels [22,23].”
MethodORIGINAL ARTICLE: Accuracy of calculated free testosterone formulae in men
Ly, L. P., Sartorius, G., Hull, L., Leung, A., Swerdloff, R. S., Wang, C., & Handelsman, D. J. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03804.x · Cited by 172 · cited 1×
“Calculated free testosterone using various formulae will give free testosterone levels depending on the formulae used and accuracy and precision of the assays for total testosterone and SHBG levels [22,23].”
Self-citationAllan, C. A., & McLachlan, R. I. (2010) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e3283398ee2 · Cited by 168 · cited 2×
“While the significant weight loss requires careful confirmation, randomized controlled trials showed that testosterone replacement therapy reduced body fat mass, regional fat distribution and waist circumference in hypogonadal men with and without obesity [48,53-61].”
Spitzer, M., Basaria, S., Travison, T. G., Davda, M. N., Paley, A., Cohen, B., Mazer, N. A., Knapp, P. E., Hanka, S., Lakshman, K. M., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-10-201211200-00004 · Cited by 163
Svartberg, J., Agledahl, I., Figenschau, Y., Sildnes, T., Waterloo, K., & Jorde, R. (2008) · International Journal of Impotence Research · doi:10.1038/ijir.2008.19 · Cited by 160 · cited 2×
“In randomized trials in middle-aged and older men, testosterone administration is associated with increase in LBM, reduction in fat mass and increase in muscle strength when compared with placebo [41,48-50].”
The analog free testosterone assay: are the results in men clinically useful?
Winters, S. J., Kelley, D. E., & Goodpaster, B. (1998) · Clinical Chemistry · doi:10.1093/clinchem/44.10.2178 · Cited by 160
Effects of Aromatase Inhibition in Elderly Men with Low or Borderline-Low Serum Testosterone Levels
Leder, B. Z., Rohrer, J. L., Rubin, S. D., Gallo, J., & Longcope, C. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031467 · Cited by 149
Outcomes of clomiphene citrate treatment in young hypogonadal men
Katz, D. J., Nabulsi, O., Tal, R., & Mulhall, J. P. (2012) · BJU International · doi:10.1111/j.1464-410x.2011.10702.x · Cited by 142
Letrozole once a week normalizes serum testosterone in obesity-related male hypogonadism
Loves, S., Ruinemans-Koerts, J., & de Boer, H. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0663 · Cited by 141
Nieschlag, E., Büchter, D., Von Eckardstein, S., Abshagen, K., Simoni, M., & Behre, H. M. (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00881.x · Cited by 140
7α-Methyl-19-Nortestosterone Maintains Sexual Behavior and Mood in Hypogonadal Men*
Anderson, R. A., Martin, C. W., Kung, A. W. C., Everington, D., Pun, T. C., Tan, K. C. B., Bancroft, J., Sundaram, K., Moo-Young, A. J., & Baird, D. T. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6028 · Cited by 97
Dalton, J. T., Taylor, R. P., Mohler, M. L., & Steiner, M. S. (2013) · Current Opinion in Supportive & Palliative Care · doi:10.1097/spc.0000000000000015 · Cited by 91 · cited 1×
“Clinical studies of these SARMs are focused on the correction of sarcopenia in elderly, patients with chronic diseases and cancer cachexia [140,141] and not for androgen replacement therapy.”
Ip, F. F., di Pierro, I., Brown, R., Cunningham, I., Handelsman, D. J., & Liu, P. Y. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0717 · Cited by 59 · cited 1×
“Testosterone replacement therapy increases hematocrit in anemic hypogonadal men in a dose dependent manner [79-81].”
Loves, S., de Jong, J., van Sorge, A., Telting, D., Tack, C. J., Hermus, A., Westerterp, K., & de Boer, H. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0190 · Cited by 45 · cited 1×
“The higher LH levels stimulate the production of endogenous testosterone in men with residual hypothalamicpituitary function, for example, aging and obesity [150-152].”
Cited by
Testosterone and Cardiovascular Disease
Kloner, R. A., Carson, C., Dobs, A., Kopecky, S., & Mohler, E. R. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.12.005 · Cited by 371
Clomiphene citrate for men with hypogonadism: a systematic review and meta‐analysis
Huijben, M., Lock, M. T. W. T., de Kemp, V. F., de Kort, L. M. O., & van Breda, H. M. K. (2022) · Andrology · doi:10.1111/andr.13146 · Cited by 65
Santos, H. O., & Teixeira, F. J. (2020) · The Aging Male · doi:10.1080/13685538.2019.1573220 · Cited by 41
“symptoms, such as very low T levels and azoospermia, the primary therapy should be hormonal replacement with T and/or hCG [42,62].”
BackgroundNovel Therapy for Male Hypogonadism
Carrasquillo, R., Chu, K., & Ramasamy, R. (2018) · Current Urology Reports · doi:10.1007/s11934-018-0816-x · Cited by 31
Oxytocin intranasal administration as a new hope for hypogonadotropic hypogonadism patients
Salehi, M. S., Pandamooz, S., & Khazali, H. (2017) · Medical Hypotheses · doi:10.1016/j.mehy.2017.09.020 · Cited by 5
“In addition, exogenous testosterone can potentially increase the risk of prostate disease [4] and develop acne and oiliness of skin because of the androgenic effects on sebaceous gland [3].”
Background
Metadata
- Authors
- Surampudi, P., Swerdloff, R. S., & Wang, C.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2014-04-23
- Volume
- 15
- Issue
- 9
- Pages
- 1247-1264
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2038766557
- Cited by
- 45
- References
- 67
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.